A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-Cell Non-Hodgkin LymphomaMedDRA version: 25.0Level: LLTClassification code: 10086816Term: B-cell non-Hodgkin´s lymphoma refractory Class: 100000004848Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-507728-22-00
- Lead Sponsor
- F. Hoffmann-La Roche AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method